

Gastric Cancer External Beam Radiotherapy Clinician Decision Tree : Updated March 2013

Gastric Cancer	Local disease M0 40%	Surgery 70%	No Radiotherapy ECRIC 98% Adjuvant CRT 45 Gy/25# ^{1,4,7} [consider if T3-4, R1 resection, nodes +ve] ECRIC 2%
		No surgery 30%	Curative intent 0% (no evidence for RT) Chemo radiotherapy 50.4/28 # /45 Gy/25# Neo adj. CRT ^{2,3,4} Radiotherapy-50.4/28# may become resectable
			Palliative intent 100% Palliative RT 30/10#, or 20 Gy/5# 5%
	Metastatic disease M1 60%	Symptoms 70%	Local symptoms from primary 30% XBRT/20 Gy/5#, 30 Gy/10#, bleeding 6-8 Gy/1# 5%
			Stenting / BSC 95% Symptomatic metastases 70% RT 20GY 5#, Single # 10%
		No symptoms 30%	No radiotherapy

Figures in red are clinical estimates

Gastric Cancer References

1. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med.* 2001 Sep 6;345(10):725-30.
2. Michael Stahl, Martin K. Walz, Martin Stuschke, Nils Lehmann, Hans-Joachim Meyer, Jorge Riera-Knorrenschild, Peter Langer, Rita Engenhart-Cabillic, Michael Bitzer, Alfred Koñigsrainer, Wilfried Budach, and Hansjochen Wilke Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction. *J Clin Oncol* 27:851-856.
3. Vincenzo Valentini, Francesco Cellini , Bruce D. Minsky , Gian Carlo Mattiucci, Mario Balducci , Giuseppe D'Agostino, Elisa D'Angelo , Nicola Dinapoli , Nicola Nicolotti , Chiara Valentini , Giuseppe La Torre. Survival after radiotherapy in gastric cancer: Systematic review and meta-analysis. *Radiotherapy and Oncology* 92 (2009) 176–183
4. Ravi Shridhar, MD, PhD, George W. Dombi, PhD, Steven E. Finkelstein, MD, Kenneth L. Meredith, MD, and Sarah E. Hoffe, MD. Improved Survival in Patients With Lymph Node-Positive Gastric Cancer Who Received Preoperative Radiation. An Analysis of the Surveillance, Epidemiology, and End Results Database. *Cancer* 2011;117:3908–16.
5. David Cunningham, M.D. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. *N Engl J Med* 2006;355:11-20.
6. Leong T, Joon DL, Willis D, Jayamoham J, Spry N, Harvey J, Di Iulio J, Milner A, Mann GB, Michael M. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group. *Int J Radiat Oncol Biol Phys.* 2011 Mar 1;79(3):690-5. Epub 2010 May 14.
7. C S Fuchs. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. © 2011 American Society of Clinical Oncology. *Journal of Clinical Oncology*, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 29, No 15_suppl (May 20 Supplement), 2011: 4003
8. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence. *Cancer.* 2004 Aug 15;101(4):657-70
9. The Royal College of Radiologists. Radiotherapy dose-fractionation. The Royal College of Radiologists, London, 2006. <http://www.rcr.ac.uk/publications>
10. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A; **ESMO Guidelines** Working Group. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010 May;21 Suppl 5:v50-4.
11. NCCN Guidelines Gastric Cancer